Skip to main content
Premium Trial:

Request an Annual Quote

Blue Heron Wins Phase I SBIR Grant to Develop Tools for Cloning Difficult Genes

NEW YORK, Sept. 9 (GenomeWeb News) - Blue Heron Biotechnology has won a Phase I SBIR grant from the National Institute of General Medical Science and the National Institute of Allergy and Infectious Disease to develop new tools for cloning genes that are "difficult" to grow in bacteria, the Bothell, Wash.-based company said yesterday.


The amount of the grant was not immediately available from the company, but NIH databases list a one-year grant entitled "High-Copy Number Cloning Of Toxic Genes" that started Aug.1 with $118,223 for fiscal year 2005.


The tools under development will block functional protein expression, thus allowing recombinant plasmids with toxic genes to be propagated in bacteria. Blue Heron plans to use the technologies to improve its GeneMaker gene synthesis service and may make it available as kits to modulate protein expression levels in E. coli.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.